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Abstract
All cells contain proteases which effect catalytic hydrolysis of the peptide bond between amino
acids in the protein backbone. Typically, proteinases are prevented from non-specific proteolysis
by regulation and physical separation into different sub-cellular compartments; however, this
segregation is not retained during cell lysis to release a protein of interest. Prevention of
proteolysis during protein purification often takes the form of a two-pronged approach; firstly
inhibition of proteolysis in situ, followed by the separation of the protease from the protein of
interest via chromatographical purification. Proteinase inhibitors are routinely used to limit the
effect of the proteinases before they are physically separated from the protein of interest via
column chromatography. Here, commonly used approaches to reducing proteolysis during
chromatography are reviewed.
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1.

Introduction

Protein stability can be defined as “the persistence of molecular integrity or biological function
despite adverse influences or conditions, such as heat or other deleterious conditions” (1). One
of the key deleterious conditions during protein chromatography is the presence of proteolytic
substances, often referred to as proteases. Proteolysis is the directed degradation of proteins by
specific proteases. Proteases have been referred to as “Nature’s Swiss Army knife” due to their
diverse applications in protein cleavage (2). Proteases belong to the hydrolase class of enzyme
(Enzyme Classification 3.4) which catalyse the hydrolysis of various bonds with the participation
of a water molecule.The proteolytic process involves the hydrolysis of the peptide bonds that
link amino acids together in the polypeptide chain. Proteases are defined as either exopeptidases
(detach the terminal amino acids from the protein chain, examples include aminopeptidases and
carboxypeptidase), or endopeptidases (which target internal peptide bonds of a protein, common
examples here include trypsin, chymotrypsin, pepsin, and papain) (3). Proteases are also divided
into four major groups according to their catalytic active site and mode of action: serine
proteinases, cysteine (thiol) proteinases, aspartic proteinases, and metalloproteinases (4).
Serine proteases, as the name suggests, have a serine residue as part of its catalytic site.
Subtilisin (EC 3.4.21.62, an endopeptidase sourced from Bacillus subtilis) is one of the most
common serine proteases examples cited (5). Cysteine proteases have a nucleophilic cysteine
thiol as part of their active site. Papain (EC 3.4.22.2, an endopeptidase sourced from Carica
papaya) is a frequently cited example of a cysteine protease (6). Aspartic proteinases use an
aspartate residue for catalysis and, in general, they have two highly-conserved aspartate residues
in the active site and are optimally active at acidic pH. Plasmepsin (EC 3.4.23.39, an
endopeptidase produced by the Plasmodium parasite) is an example of an aspartic proteinase (7).

Metalloproteinases contain a catalytic mechanism involving a metal; most contain zinc, however,
cobalt centres are also observed. Adamalysin (EC 3.4.24.46, an endopeptidase from the
rattlesnake Crotalus adamanteus) is an example of a metalloproteinase (8).

Proteases are employed by all living cells to maintain a particular rate of protein turnover by
continuous degradation and synthesis of proteins. Catabolism of proteins provides a ready pool
of amino acids that can be reused as precursors for protein synthesis. Intracellular proteases
participate in executing correct protein turnover for the cell: in E. coli, the ATP-dependent
protease La, the lon gene product, is responsible for hydrolysis of abnormal proteins (9). The
turnover of intracellular proteins in eukaryotes is also affected by a pathway involving ATPdependent proteases (10).
As such, proteases are essential components in all life forms and in normal circumstances
proteases are typically packaged into specialised organelles to minimise the chance of nonspecific proteolytic activity. Within these organelles there are specific regulators associated with
each protease, controlling the action of the protease. However, when cells are disrupted for
chromatography purification, proteases that are normally located in a different sub-cellular
compartment are separated from their regulator molecules and exposed to the protein of interest,
thus increasing the probability of undesired proteolysis (11). Realistically, it is impossible to
remove all proteinases present in a chromatography sample preparation, however, careful
selection of host cell (if protein of choice is recombinantly expressed) or cell type (if the protein
of choice is native) in conjunction with specific sample preparation protocols can reduce
unwanted proteolysis during purification (3).

Proteases are ubiquitous and play a crucial role in normal and abnormal physiological conditions
in all living things by effecting catalysis throughout many metabolic pathways. However, there is
an uneven distribution of proteinases depending on which cell type (bacterial or eukaryotic) or
tissue is disrupted. During heterologous protein expression, the recombinant protein of interest
may be exposed to a host proteinase to which it is particularly susceptible. Simply altering the
host may reduce recombinant proteolysis. Many commercial companies offer protease deficient
strains for heterologous protein expression; for example E. coli BL21, is deficient in two
proteases encoded by the lon (cytoplasmic protease) and ompT (periplasmic protease) genes (see
Table 1). Additionally in mammalian tissues, liver and kidney samples contain a much higher
concentration of proteolytic enzymes compared to skeletal or cardiac muscle (12). Once the
source of the protein of choice has been optimized, a commonly used approach toward
prevention of further unwanted proteolysis during protein isolation is to include proteinase
inhibitors during sample preparation, purification, and characterization.

INSERT TABLE ONE ABOUT HERE

1.1

Proteinase Inhibitor Selection and Preparation.

Judicious inhibitor choice will depend on the correct empirical identification of the proteinase
involved. Classification of the proteinase(s) can be carried out in several ways, however, the
simplest method is to incubate the sample of choice with a single inhibitor from the group of
inhibitors (Serine, Cysteine, Thiol etc.) listed in Table 2. The degree of proteolysis can be
identified from Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS PAGE)
analysis of the protein sample post inhibitor incubation; increased protein band smearing on the

gel or a change in expected protein size will indicate potential proteolysis. Proteolysis inhibition,
indicated by a maintenance of correct protein size with no protein band smearing after a given
incubation period with inhibitor, will permit the identification of a suitable inhibitor group for
the sample preparation. Once the protease has been identified, individual inhibitors can be
chosen from Table 2 or a typical general-use proteinase inhibitor mix can be prepared
immediately before use from the stock concentrations outlined in Table 3. Proteinase inhibitor
solutions must be correctly stored after they have been prepared. Aliquot the stock of inhibitor
and store at the correct temperature (see Table 2) to maintain the properties of the inhibitor.
Make small, single use aliquots to reduce the risk of stock contamination. Ensure that the
proteinase inhibitor/inhibitor mix is combined with the cell sample prior to cell disruption. If the
individual proteinase inhibitor/inhibitor mix is to be prepared fresh then it must be used within
one hour of preparation.

INSERT TABLE TWO ABOUT HERE.

INSERT TABLE THREE ABOUT HERE.

It should be noted that the generic proteinase inhibitor cocktail outlined here is not guaranteed to
work in all circumstances. The success of any mix will depend on the correct empirical
identification of the proteinase involved.

1.2

Commercially available Universal Protease Inhibitor Mixes.

There are several types of commercially available “Universal Proteinase Inhibitors” that may
also be used (e.g. Complete Protease Inhibitor Cocktail Tablets, Roche Applied Science).
Additionally, many companies offer inhibitor panels, such as the Protease Inhibitor Panel
(Sigma Aldrich), which is a cost-effective method for personalized proteinase cocktail inhibitor
generation (13).

1.3

Supplementary Protease Inhibitor Components.

Additional Inhibitors
If a particular protease is dominant within a sample preparation the cocktail mix may be
supplemented with additional specific proteinase inhibitors (12,14 - 21). Commonly used
specific individual protease inhibitor components are outlined in Table 4.

INSERT TABLE FOUR ABOUT HERE.

Phosphatase inhibitors may be required also as many enzymes are activated by phosphorylation,
hence dephosphorylation must be inhibited if enzyme activity is to be maintained. Again, an
empirical approach is required to identify if a phosphatase inhibitor is required (see Section 1.1
and Table 5). Protein phosphatases can be divided into two main groups: protein tyrosine
phosphatases and protein serine/threonine phosphatases which remove phosphate from proteins
(or peptides) containing phosphotyrosine or phosphoserine/phosphothreonine respectively (22).
Inhibitors commonly used here include: p-Bromotetramisole, Cantharidin, Microcystin LR
(Ser/Thr Protein Phosphatases and Alkaline Phosphatase L-Isozymes) and Imidazole, Sodium

molybdate, Sodium orthovanadate, Sodium tartrate (Tyr Protein Phosphatases and Acid and
Alkaline Phosphatases, see Table 5). There are also a number of commercially available
Phosphatase Inhibitor Mastermixes (e.g. PhosphataseArrest™ Phosphatase Inhibitor Cocktail,
Geno Technologies Ltd.). These are often supplied in convenient, ready-to-use 100X solutions
that are simply added to the protein extraction buffer or individual samples. These mixes can be
sourced as either broad spectrum phosphatase inhibitor cocktails or as phosphatase inhibitors for
targeting particular set of phosphatases.

INSERT TABLE FIVE ABOUT HERE.

1.4

Supplementary Chemical Compounds including Enzymes.

The addition of supplementary chemical components to disrupt proteinase activity first should be
carefully assessed on a small scale as often these components will alter the function/stability of
the target protein (see Table 6). Furthermore, additional protease inhibitors should be introduced
to the sample with caution as protein modifications, such as alteration of protein charge, may
occur. These alterations may interfere with further protein characterisation studies. For example,
2-mercaptoethanol will reduce the activity of cysteine proteinases, but will also unfold target
proteins containing disulphide bridges. EDTA is included in many proteinase inhibitor buffers as
metal ions are frequently involved in proteolysis, thus their removal will impede proteolysis.
However, if one is purifying poly-Histidine tagged proteins or metalloproteins, then the chelating
effect of EDTA will dramatically alter purification yields, and the EDTA should be removed
from the buffer by dialysis or a buffer exchange resin. Inclusion of 2 M thiourea may also
prevent proteolyis. Castellanos-Serra and Paz-Lago (23) noted the proteolysis inhibitory effects

of its addition in conjunction with its efficiency in solubilizing proteins. DNase (100 U/mL),
although not itself a protease inhibitor, can be included in the cell lysis buffer as this will reduce
the overall viscosity of the crude lysate. The reaction is allowed to proceed for 10 min at 4°C in
the presence of 10 mM MgCl2.

INSERT TABLE SIX ABOUT HERE.

1.5

Protease Inhibition During Chromatography.

The introduction of contaminating proteases from your own skin, non-sterile water etc. can be
avoided by sterilising all plasticware and by wearing appropriate personal protective equipment.
All buffers should be sterile filtered (0.2 µm) into autoclaved bottles (sterile filtering will not
remove contaminating proteases, but will remove any protease secreting microorganisms).
Additionally, sterile filter the protein eluate once purification is complete.

Cell disruption, as with all other parts of the purification procedure, should take place at 2-8oC.
This temperature will not only reduce the activity of proteinases, but will also aid in stabilizing
the target protein (reduction in thermal denaturation). Kulakowska-Bodzon and co-workers (24)
provide an excellent review on protein preparation from various cell types for proteomic work.
In general, all buffers and materials should be pre-chilled to 2-8oC. Rapid purification at this
lower temperature will reduce the risk of unwanted proteolysis. Do not store such samples at 28oC for more than one day between purification steps, instead store at -20°C.

Gel filtration (size exclusion chromatography, see Chapter 2) is often used as the final step in
protein purification and it can be used to desalt and buffer exchange the protein (therefore no
need for dialysis). Contaminating proteinases can also be separated from the protein of choice if
there is significant separation between elution peaks for the protease and the protein of choice.
This is based on the presumption that there is a considerable difference between the size of the
protease and the size of the protein of interest.

1.6

Post Chromatography Analysis.

Protease inhibition can be either reversible or irreversible. The majority of serine and cysteine
proteinase inhibitors are irreversible, whereas the aspartic and metalloproteinase inhibitors are
reversible. Even when the inhibitors are added at an early stage, they may be lost during
purification and subsequent handling steps, resulting in proteolysis post-purification. The further
re-addition of proteinase inhibitors may therefore be required after purification.

Even with increased numbers of purification steps, very few protocols will remove all
contaminants from a sample preparation however one can achieve an adequate reduction in the
level of these contaminants. Each purification protocol will have a unique definition of
“adequate protease reduction” based on a number of variables including the activity of the
remaining proteases, further downstream applications of the protein of choice and the cost of
further protease removal. Increased purification steps often result in a reduced final yield, as such
the trade-off between contaminant reduction and yield must be optimised. A pure protein that
gives a single band on a Coomassie-stained SDS-PAGE gel should be re-analysed over time to
ensure minimal proteinase activity exists in the sample. This may be carried out by simply

storing an aliquot of the purified protein solution at room temperature and analysing samples of
this by SDS-PAGE at regular intervals. If the protein is being degraded (indicated by a smear or
a reduced size of the protein of choice), proteinase contamination is present and an additional
purification step (or supplemental inhibitor addition) is required.

Some purification protocols require the addition of specific proteases such as enterokinase
(recognition site D-D-D-K) or TEV protease (recognition site E-N-L-Y-F-Q-G) to remove
polypeptide tags from recombinant proteins. Ensure that any proteinase inhibitor containing
buffer is exchanged, by dialysis or a suitable buffer exchange resin, prior to the addition of the
desired proteinase (see also Chapter 19).

Care must be taken to rule out the possible loss of enzyme activity due to other destabilizing
factors during protein purification. These other factors include, but are not limited to, thermal
denaturation, oxidative damage and column surface adherence. Thermal denaturation of proteins
is the decreased stability of a protein caused by extremes of temperature experienced by the
protein of interest. Thermal denaturation can be reduced if the purification procedure is carried
out at 2-8oC, all buffers and chromatography columns/resins are pre-chilled to 2-8oC and if the
purified protein is stored at the correct temperature post-purification. Oxidative damage to
proteins can be divided into a number of sections; however improper disulfide formation is the
most pertinent here. Thiol oxidation is crucial for correct protein folding, resulting in a stabilized
3-D protein structure in proteins containing disulphide bridges. The formation of incorrect intraor intermolecular disulfides is a detrimental process that can often result in loss of activity and/or
aggregation. Thiol oxidative damage can be avoided by not exposing the protein of choice to

thiol reducing compounds (e.g. β-mercaptoethanol) during purification, thus maintaining the
correct folded state of the protein. Column surface adherence is caused by the attraction of the
protein of choice to the surface of the purification column by the protein’s intrinsic physicochemical properties (e.g. surface charge or hydrophobicity). Non-specific protein adherence can
cause sheer stress damage to the protein during purification, however this can be circumvented
by careful selection of the purification column (type/grade of glass or plastic) and purification
resin.

2.0

Conclusion.

The presence of proteolytic enzymes can result in target protein degradation during protein
chromatography. Careful selection of source organism/tissue, along with judicious use of
protease inhibitors, can reduce these degrading effects. Commonly used inhibitors are listed here
in tabular format (see Tables 3 and 4), along with supplemental compounds (see Tables 5 and 6)
for easy selection. Protease inhibitors can be added individually or as part of a mix, however,
optimal inhibitor selection is an empirical process.
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Table 1: Some commercially available protease-deficient E. coli strains that are used to express
recombinant proteins.
Strain Name

Protease Deficiency

Supplier

Deficient in OmpT (an outer
New England Biolabs Inc.
membrane protease that cleaves
between sequential basic amino acids).
Deficient in Lon (a protease that
New England Biolabs Inc.
degrades abnormal/misfolded
proteins).

UT5600

CAG626

CAG597

Stress-induced proteases at high
temperature.

New England Biolabs Inc.

CAG629

Stress-induced proteases at high
temperature and Lon protease.

New England Biolabs Inc.

PR1031

Deficient in DnaJ –a chaperone that
can promote protein degradation.

New England Biolabs Inc.

KS1000

Deficient in Prc (Tsp), a periplasmic
protease.

New England Biolabs Inc.

Rosetta

Deficient in Lon and OmpT.

Novagen

Rosetta-gami B

Deficient in Lon and OmpT.

Novagen

Origami B

Deficient in Lon and OmpT.

Novagen

.

Deficient in Lon and OmpT.

Invitrogen

.

Deficient in Lon and OmpT.

Invitrogen

Deficient in Lon and OmpT.

Invitrogen

BL21 Star (DE3)pLysS
BL21 Star (DE3)
BL21-AI

Table 2: Protease-Inhibitors: Stock Solutions and Storage Conditions.
Inhibitor Activity

Inhibitor

Solvent

Molarity

Storage

Serine

PMSF1

dry methanol or propanol

200 mM

-20oC

Serine

3,4-DCL

dimethylsulfoxide

10 mM

-20oC

Serine

Benzamidine

water

100 mM

-20oC

Cysteine

Iodoacetic acid

water

200 mM

Prepare fresh

Cysteine

E64-c

water

5 mM

-20oC

Leupeptin

water

10 mM

-20oC

Metallo

1,10 Phenanthroline

methanol

100 mM

RT3 or 4oC

Metallo

EDTA2

water

0.5 M

RT3 or 4oC

Acid Proteases

Pepstatin

DMSO

10 mM

-20oC

Aminopeptidase

Bestatin

water

5 mM

-20oC

Thiol (serine & cysteine)

1

PMSF is toxic. Weigh this compound in a fume hood, and wear appropriate personal protective

equipment.
2

Does not inhibit pancreatic elastase.

3

RT - Room Temperature.

Table 3: General proteinase inhibitor mix
Stock Inhibitor

Volume (µL)

PMSF (100 mM) or 3,4-DCI (10 mM) or Benzamidine (5 mM)

200

Iodoacetate (200 mM) or E64-c (5 mM)

200

1,10 phenanthroline (100 mM) or EDTA (500 mM) or Leupeptin (10 mM)

100

Pepstatin (10 mM)

100

Double Distilled Water

400

Final Volume

1,000

Table 4. Additional inhibitors that can be used to supplement protease inhibitor mixes.
Inhibitor

Solvent

Molarity

Storage

water

300 mM

-20oC (at pH 7)

DMSO

10 mM

-20oC

water

10 Units/mL

-20oC (at pH 7)

TLCK (Inhibits chymotrypsin-like serine proteases)

1 mM HCl

100 µM

Prepare fresh

TPCK (Inhibits chymotrypsin-like serine proteases)

Ethanol

10 mM

4 oC

DIFP (Highly toxic cholinesterase inhibitor. Broad

anhydrous

200 mM

-20oC

spectrum serine protease inhibitor. Hydrolyzes rapidly in

isopropanol

water

10 mM

-20oC

water

100 mM

-20oC

water

100 mM

Prepare fresh

water

1 mM

-20oC

Serine Protease Inhibitors
Aprotinin (Does not inhibit thrombin or factor Xa)
Chymostatin (Inhibits chymotrypsin-like serine proteases
such as chymase cathepsins A,B,D and G. Also inhibits
some cysteine proteases such as papain)
Antithrombin III (Inhibits thrombin, kallikreins, plasmin,
trypsin and factors Ixa, Xa, and Xia)

aqueous solutions)
Antipain (Inhibits serine proteases such as plasmin,
thrombin and trypsin. Also inhibits some cysteine
proteases such as calpain and papain)
α2-Macroglobulin (Broad spectrum protease inhibitor)

Cysteine Protease Inhibitors
N-Ethylmaleimide

Metalloproteinase Inhibitors
Phosphoramidon (Strong inhibitor of
metalloendoproteinases, thermolysin and elastases, but a
week inhibitor of collagenase)

Table 5: Commonly used phosphatase inhibitors.
Name

Typical Working Molarity Range

Stock Molarity

Typical Inhibitory Targets.

p-Bromotetramisole

0.1 – 1.5 mM

100 mM

Alkaline Phosphatases (25, 26)

Cantharidin

20 – 250 µM

2.5 mM

Protein Phosphatase 2-A (25, 27)

Microcystin LR

20 – 250 nM

2.5 µM

Protein Phosphatase 1 and 2-A
(25, 28)

Imidazole

50 – 200 mM

1M

Alkaline Phosphatases (29, 30)

Sodium molybdate

50 – 125 mM

1M

Acid phosphatases and
Phosphoprotein Phosphatases
(27, 30)

Sodium orthovanadate

50 – 100 mM

1M

ATPase inhibition, Protein
Tyrosine Phosphatases,
Phosphate-transferring enzymes.
(30, 31)

Sodium tartrate

50 – 100 mM

1M

Acid Phosphatases (28, 30).

Table 6: Supplemental chemical/enzyme additions to protease inhibitor buffer (32).
Item and typical working

Advantages

Disadvantages

Uses / Typical Protease

concentration
2-mercaptoethanol (1 mM)

Targets
Reduction cysteine

Unfolding of target proteins

proteinase activity.

containing disulphide

Cysteine Proteases

bridges
EDTA

Removal of metal ions

The chelating effect of

Non-His tagged protein

(5 mM)

involved in proteolysis

EDTA will affect the

targets or non-metalloprotein

impeding proteolysis

structure of metalloproteins

targets.

and dramatically reduce the
purification of polyHistidine tagged proteins.
Thiourea

Proteolysis inhibitory

Thiourea is considered a

General purpose protease

(2 M)

effects, in conjunction with

possible human carcinogen

inhibitor.

improved protein

and mutagen.

solubilisation.
DNase

Reduction in the crude lysate

Requires further incubation

Can be included in the cell

(100 U/mL)

viscosity.

step of 10 min at 4°C in the

lysis buffer for optimal

presence of 10 mM MgCl2.

efficiency.

